Mineralys Therapeutics Inc
MLYS39.270USD
-0.600-1.50%
收盘 09/19, 16:00（美东）报价延迟15分钟
2.58B总市值
亏损市盈率 TTM
关于 Mineralys Therapeutics Inc 公司
Mineralys Therapeutics, Inc. 是一家临床阶段的生物制药公司。该公司专注于开发针对高血压、慢性肾病 (CKD) 和其他由醛固酮异常升高引起的疾病的药物。该公司的候选产品 lorundrostat 是一种专有的口服高选择性醛固酮合酶抑制剂 (ASI)，该公司最初正在开发用于治疗不受控制的高血压 (uHTN) 患者。Lorundrostat 旨在通过抑制负责产生激素的酶 CYP11B2 来降低醛固酮水平。该公司完成了 Target-HTN 试验，这是一项针对 lorundrostat 治疗 uHTN 的 II 期概念验证试验。除了高血压之外，该公司还打算开发用于治疗慢性肾病 (CKD) 的 lorundrostat。
公司简介
公司代码MLYS
公司名称Mineralys Therapeutics Inc
上市日期Feb 10, 2023
CEOMr. Jon Congleton
员工数量51
证券类型Ordinary Share
年结日Feb 10
公司地址150 N. Radnor Chester Road
城市RADNOR
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编19087
电话18883786240
网址https://mineralystx.com/
公司代码MLYS
上市日期Feb 10, 2023
CEOMr. Jon Congleton
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
678.62K
-2.29%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
62.70K
-57.38%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. Derek Dirocco, Ph.D.
Dr. Derek Dirocco, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月5日 周五
更新时间: 9月5日 周五
持股股东
股东类型
持股股东
持股股东
占比
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
Capital International Investors
3.84%
其他
63.02%
持股股东
持股股东
占比
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
Capital International Investors
3.84%
其他
63.02%
股东类型
持股股东
占比
Venture Capital
33.14%
Investment Advisor
22.23%
Hedge Fund
19.75%
Investment Advisor/Hedge Fund
14.93%
Private Equity
5.26%
Individual Investor
1.87%
Research Firm
1.42%
Bank and Trust
0.17%
Pension Fund
0.12%
其他
1.13%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
287
68.74M
105.48%
+8.03M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
2023Q1
99
41.30M
101.10%
+30.53M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Catalys Pacific, LLC
8.64M
13.26%
--
--
Mar 31, 2025
RA Capital Management, LP
6.15M
9.43%
+1.30M
+26.72%
Mar 31, 2025
Samsara BioCapital, LLC
5.67M
8.71%
+600.00K
+11.82%
Mar 31, 2025
SR One Capital Management, LP
3.13M
4.8%
+1.11M
+55.09%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.20M
3.38%
+266.41K
+13.75%
Mar 31, 2025
Integral Health Asset Management, LLC
2.30M
3.53%
+1.43M
+162.86%
Mar 31, 2025
The Vanguard Group, Inc.
2.04M
3.12%
+603.46K
+42.14%
Mar 31, 2025
HBM Partners AG
2.25M
3.45%
--
--
Sep 30, 2024
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.12%
SPDR S&P Biotech ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.13%
iShares Micro-Cap ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.09%
Vanguard US Momentum Factor ETF
0.08%
iShares Biotechnology ETF
0.06%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
iShares Russell 2000 Growth ETF
0.04%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.12%
SPDR S&P Biotech ETF
占比0.2%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.13%
iShares Micro-Cap ETF
占比0.13%
ProShares Ultra Nasdaq Biotechnology
占比0.1%
Invesco Nasdaq Biotechnology ETF
占比0.09%
Vanguard US Momentum Factor ETF
占比0.08%
iShares Biotechnology ETF
占比0.06%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.04%
iShares Russell 2000 Growth ETF
占比0.04%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
